New antiretrovirals and TB drug interactions

Gary Maartens



OF CAPE TOWN

First line TB regimens

• New TB regimens are being investigated for treatment shortening, but

progress has been slow


• Rifampicin remains key 1st line drug for TB for the medium term

Rifampicin induction

Enzyme/transporter	ARV substrate
CYP3A4 (55.1-fold)	PIs, NVP
CYP2B6 (8.8-fold)	EFV, NVP
P glycoprotein (3.5-fold)	Pls TAF
BCRP	TAF
UGT1A1	Raltegravir Dolutegravir

J Pharmacol Exp Ther 2001;299:849 Pharmacol Rev 2013;65:944–966


Raltegravir & rifampicin




Wenning AAC 2009

ANRS REFLATE: EFV- vs RAL-based ART in TB


- Multicenter, randomized, open-label phase II trial
 - Primary endpoint: HIV-1 RNA < 50 copies/mL at Wk 24



REFLATE – VL outcomes



Dolutegravir & rifampicin



JAIDS 2013;62:21

Dolutegravir adjusted doses in TB

- Absorption is saturable, so doubling the daily dose is not an option
- Clearance is increased and estimated C_{min} is about the same as IC90
- Therefore 12 hourly dosing is likely to be necessary
- INSPIRING study will assess PK of DTG 12 hourly in patients with TB & evaluate efficacy (not powered versus comparator though)
- Need an adequately powered RCT of virologic efficacy of DTG 12 hourly (plus 2 NRTI) against the current standard of care (EFV, TDF, FTC) in patients with TB

Cobicistat


- CYP3A4 inhibitor used as a pharmacoenhancer for PIs & elvitegravir
- Compared with ritonavir:
 - Not an antiretroviral
 - No inducing effect
 - Relatively more specific for CYP3A4
 - Easier to co-formulate with PIs
- Cobicistat is a substrate of CYP3A4, so its metabolism can be induced by rifampicin
- Need to investigate whether increased doses of cobicistat-boosted PIs can overcome induction by rifampicin

Adjusted dose PIs & rifampicin: healthy volunteers

- Very high rates of hepatitis reported in 3 healthy volunteer studies (Saquinavir, Atazanavir, Lopinavir); all stopped early due to toxicity
- ?relevant to HIV+ patients: e.g. rif + PZA for LTBI well tolerated in HIV+, but not in HIV-

Arch Drug Inf. 2009 Mar;2(1):8-16 AIDS 2008;22:931-5 JAIDS 2009;50:290-3 CID 2004;39:561

Double dose LPV/r with rifampicin: HIV+ adults on 2nd line ART, VL <400




2/21 asymptomatic grade 3/4 ALT 0/18 grade 3/4 ALT in TB patients

Pls and rifampicin-based ART

- Need to investigate adjusted doses of boosted atazanavir & darunavir in patients
- Assess PK effects when boosted with cobicistat & ritonavir
- Need data in young children

Tenofovir Alafenamide vs TDF: Pharmacokinetics



Tenofovir Alafenamide

- TAF is a substrate of the drug transporters P-glycoprotein, OATP1B1, OATP1B3 and BCRP; and also (minimal) CYP3A4
- When co-administered with cobicistat (an inhibitor of P-gp, OATP1B1, OATP1B3, BCRP and CYP3A4) the dose of TAF is reduced from 25 mg to 10 mg (versus modest 23% [↑]AUC for TDF, requiring no dose adjustment).
- Rifampicin induces CYP3A4, P-gp, and BRCP; and inhibits (!) OATP1B1 and OATP1B3 – the nett effect is unknown (package insert: coadministration not recommended)
- Urgent need for a PK study with rifampicin, endpoint intracellular tenofovir-DP